The science behind Cardihab

Cardihab's Remote Cardiac Rehabilitation solution provides clinicians with the ability to remotely deliver a scientifically validated, comprehensive Phase II cardiac rehabilitation program that is based on Australian guidelines. This model of care we implement was scientifically validated in a world first, randomised controlled trial (RCT) by researchers from CSIRO and The Prince Charles Hospital via the Australian E-Health Research Centre.

The RCT demonstrated that the model of care underpinning our product improves patient uptake (+29%), adherence (+38%) and completion (+70%), while significantly reducing the number of centre visits (-86%) and delivering equivalent clinical outcomes when compared to centre-based care. Importantly, both patients and clinicians report positive experiences of remote delivery in research and subsequent "business as usual" settings.

The research provides the evidence base for Cardihab's product and was published in the prestigious journal Heart. The paper was also acknowledged by Heart and Nature Reviews Cardiology as a world-first randomised controlled trial of smartphone-based cardiac rehabilitation. These papers, along with follow up academic work conducted by CSIRO and other research partners are listed below.